15548-23-9

Upstream product

• 2030-53-7 (+/-)-roemerine 
• 71524-02-2 (S)-7-methyl-11-(1-phenyl-1H-tetrazol-5-yloxy)-6,7,7a,8-tetrahydro-5H-benzo[g][1,3]dioxolo[4',5':4,5]benzo[1,2,3-de]quinoline 
• 87201-30-7 N-<-2-(3,4-methylenedioxyphenyl)ethyl>-2'-bromophenylacetamide 
• 1484-85-1 3,4-methylenedioxyphenylethylamine 
• 87201-31-8 1-(2'-bromobenzyl)-3,4-dihydro-6,7-methylenedioxyisoquinoline 
• 65981-49-9 (S)-11-methoxy-7-methyl-6,7,7a,8-tetrahydro-5H-benzo[g][1,3]dioxolo[4',5':4,5]benzo[1,2,3-de]quinoline 
• 3466-56-6 (+)-mecambroline 
• 1093-07-8 (-)-mecambrine 

Downstream Products

• 548-08-3 (+)-roemerine 
• 548-08-3 roemerine 
• 475-75-2 liriodenine 
• 36285-03-7 dehydroroemerine 

Relevant academic research and scientific papers

Synthesis and evaluation of nuciferine and roemerine enantiomers as 5-HT2 and α1 receptor antagonists

In this study, the (S)-enantiomers of the aporphine alkaloids, nuciferine and roemerine, were prepared via a synthetic route involving catalytic asymmetric hydrogenation and both stereoisomers were evaluated in vitro for functional activity at human 5-HT2 and adrenergic α1 receptor subtypes using a transforming growth factor-α shedding assay. Both enantiomers of each of the compounds were found to act as antagonists at 5-HT2 and α1 receptors. (R)-roemerine was the most potent compound at 5-HT2A and 5-HT2C receptors (pKb = 7.8-7.9) with good selectivity compared to (S)-roemerine at these two receptors and compared to its activity at 5-HT2B, α1A, α1B and α1D receptors.